Archimed taking Esperion private in $1.1bn deal
Pharmaceutical company Esperion Therapeutics has announced it has entered into a definitive agreement to be acquired by the healthcare focused investment firm Archimed in a $1.10bn deal. Esperion, a commercial-stage biopharma group dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, has faced competitive pressures in the lipid lowering market and looking forward, will need to contend with…